Jasper Therapeutics disclosed a compromised drug lot that affected data integrity in a Phase 1b/2a trial for its leading urticaria treatment, briquilimab. The issue has prompted uncertainty about ongoing trial results and led to a sharp decline in the company's stock price. Jasper is considering restructuring to maintain financial stability. This development raises questions on manufacturing controls and trial reliability in emerging biotechs.